MHS

(redirected from RYR1)
Also found in: Medical, Acronyms, Encyclopedia.

MHS

Copyright © 2012, Campbell R. Harvey. All Rights Reserved.

MHS

A debt security whose value is derived from mortgages on manufactured houses. This entitles the owner to a claim on the principal and interest payments on the particular mortgages underpinning the security. MHSs pay an interest rate that is usually related to the interest rates the homeowners are paying on their mortgages. The equivalent of the coupon on a mortgage backed security is a percentage of the interest and principal paid on the mortgages backing the security. MHSs are subject to many of the same risks as conventional mortgage-backed securities, but they carry an additional risk of depreciation. Unlike most homes, manufactured houses have a greater risk of losing value over time.
Farlex Financial Dictionary. © 2012 Farlex, Inc. All Rights Reserved
References in periodicals archive ?
To validation of differentially expressed for differentially methylated genes between groups, we confirmed twelve differentially methylated genes in MeDIP-seq by real-time quantitative PCR, including TGFB3, ACSL1, ryanodine receptor 1 (RYR1), ACOX2, peroxisome proliferator activated receptor-gamma2 (PPARG2), netrin 1 (NTN1), RIN2, microtubule associated protein RP/EB family member 1 (MAPRE1), ADAM metallopeptidase with thrombospondin type 1 motif 2 (ADAMTS2), myomesin 1 (MYOM1), ZDHHC13, and SH3 and PX domains 2B (SH3PXD2B).
Briefly, samples were first exposed to a mouse monoclonal primary antibody which recognizes both RYR1 and RYR3 (34C, 1: 20; Developmental Studies Hybridoma Bank, University of Iowa) and then to a Cy3 goat anti-mouse IgG secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, PA, USA).
A second possibility is that activation of spatially segregated RyR1 and RyR2 channels creates [Ca.sup.2+] microdomains within the soma and the dendritic processes and terminals (Berridge 2006) whose coincident activation is necessary for enhancing activity-dependent dendritic growth.
In support of this hypothesis, we observed that the selective RyR antagonist, FLA365, as well as siRNA knockdown of either RyR1 or RyR2, completely blocked BIC-induced dendritic growth in both dissociated cultures of hippocampal neurons and hippocampal slice cultures.
Only three patients (numbers 1, 2 and 18) had undergone RYR1 gene analysis in a previous study20,21.
The accelerated group included two individuals carrying an RYR1 mutation and two patients who had experienced an MH episode (CGS 5-6).
We report here on a novel protocol for denaturing HPLC (DHPLC) mutation screening of the human RYR2 gene, based on clustering of known mutations along the RYR1 and RYR2 genes.
RESULTS: PBDEs possessing two ortho-bromine substituents and lacking at least one para-bromine substituent (e.g., BDE-49) activate RyR1 and RyR2 with greater efficacy than corresponding congeners with two para-bromine substitutions (e.g., BDE-47).
Key Words: malignant hypothermia, genetics, diagnosis, physiopathology, DNA sequencing, RYR1, ryanodine receptor, calcium release channel, in vitro contracture test, novel mutation, general anaesthesia, chromosome 19
Topics include reconstruction of glutamine synthetase using computer averaging, a cryo-electron microscopic study of ribosome-bound termination factor RF2, the process of mRNA-tRNA translocation, and the structural basis for gating and activation of RyR1. ([umlaut] Ringgold, Inc., Portland, OR)
In addition, we identified 4 rare damaging variants in RYR1 and 1 in CACNA1S.